AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: ULTOMIRIS (Alexion Pharmaceuticals, Inc.) (ultomiris.com)
This is a low-BS, high-substance pharmaceutical site. It prioritizes clinical evidence and mandatory safety information over marketing narratives, providing users with technical specifications rather than vague promises.
Improve the homepage H1 hierarchy to mirror the high specificity of the sub-pages. Ensure that all clinical trial results are linked directly to their ClinicalTrials.gov registry numbers for maximum transparency. Consider adding a ‘Professional’ vs ‘Patient’ toggle more prominently to separate high-density technical data from patient resources. Update the 2024 dated references on the aHUS page to maintain the ‘current’ credibility modifier for 2026.
The information density is exceptionally high for a patient-facing site. Headings like ‘People taking ULTOMIRIS had ZERO relapses during the clinical trial’ provide immediate, quantifiable outcomes rather than fluff. The body text is dominated by technical safety protocols and specific dosing schedules (e.g., ‘1,100 mg/11 mL’ in the gMG schema), resulting in a very low fluff-to-substance ratio.
Breadcrumbs, clusters, and parent child paths must exist in the HTML — not just in schema. Start your free link graph inspection and see whether your hierarchy survives a machine level crawl.
There is virtually zero semantic drift between pages. The homepage acts as a gateway to four specific indications (NMOSD, gMG, aHUS, PNH), and the sub-pages deliver deep clinical data for exactly those conditions. The primary signal of ‘long-acting treatment’ is consistently backed by the 8-week dosing interval mentioned across all sub-pages.
Transition from a collection of strings to a machine verifiable identity. Generate your Clinical SEO Strategy to establish a robust Knowledge Graph Topology and eliminate semantic black holes.
The site avoids traditional trust theatre like unverified 5-star reviews. Instead, it relies on FDA-regulated proof paths, including full Prescribing Information and the REMS program. While it uses a patient story (Kass’ story), it explicitly labels images as ‘Actor portrayal,’ which is a high-integrity signal in medical marketing.
The ratio of verifiable evidence to assertions is high. For every marketing headline about ‘freedom,’ there is a corresponding technical specification regarding infusion frequency (6-7 times per year) or clinical results. The use of a ‘Patient Safety Card’ and specific 16-week monitoring periods for PNH demonstrates high clinical accountability.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
The site does carry some industry-standard clichés such as ‘enjoy her journey’ and ‘moving forward with continuous symptom control.’ However, these are anchored to unique value propositions like being the ‘1st and only long-acting C5 inhibitor.’ The template language is specific to Alexion (OneSource support program) rather than generic boilerplate.
Authority is well-established through detailed JSON-LD schema on the gMG page, which identifies the manufacturer (Alexion Pharmaceuticals) and the specific drug mechanism. There are no major authority gaps; the site clearly identifies itself as an official brand property and provides professional-grade regulatory documentation.
The performance claims are bold but strictly quantified. Claiming a ‘98.6% reduced risk of relapse’ is a massive performance assertion that is immediately qualified by placebo-controlled clinical trial data. The marketing tone is secondary to the regulatory and clinical substance.
Medical Devices, Pharma & Biotech BS: ULTOMIRIS (Alexion Pharmaceuticals, Inc.) (ultomiris.com)
The website perfectly aligns with the Pharma and Biotech industry. The high volume of mandatory Important Safety Information (ISI), Boxed Warnings, and specific clinical trial data (98.6% reduction in relapse) confirms a highly regulated medical product site.
If your entity graph is unstable, every other part of the framework inherits that instability. Study the Structured Data Framework Guide and see why schema is not markup — it is the machine readable definition of your domain.
“The score of 16 is driven by the site's extreme specificity and adherence to regulatory transparency. Most points were lost in the Commodity Fingerprint pillar due to standard pharma 'patient journey' cliches, but the Information Density and Semantic Coherence pillars are nearly flawless.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 24, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at ULTOMIRIS (Alexion Pharmaceuticals, Inc.) to view the most current version of their content and see directly what the company offers.